tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Burke GW et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: lack of impairment of glycemic or lipid metabolism. 1995 Transplant. Proc. pmid:8539872
Watanabe K et al. Fate of long-surviving allografts in tolerant recipients induced by fractionated lymphoid irradiation, donor bone marrow cell infusion, and FK 506 after retransplantation in dogs. 1993 Transplant. Proc. pmid:7679813
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Takahashi K et al. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24655975
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Wu MJ et al. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5. 2014 Transplant. Proc. pmid:24655974
Ryu S and Yasunami Y Prevention of immune rejection in rat islet allografts by continuous SC administration of FK 506 using a mini-osmotic pump. 1991 Transplant. Proc. pmid:1703710
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Urbizu JM et al. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience. 2002 Transplant. Proc. pmid:11959197
Pascual J and Ortuño J Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy. 2002 Transplant. Proc. pmid:11959198
Gamboa O et al. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation. 2011 Transplant. Proc. pmid:22099798
Shapiro R et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. 1998 Transplant. Proc. pmid:9636557
Grewal HP et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. 1998 Transplant. Proc. pmid:9636558
Fernández A et al. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. 2009 Jul-Aug Transplant. Proc. pmid:19715915
Rodrigo E et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. 2005 Transplant. Proc. pmid:15866635
Chueh SC et al. Drug fever caused by mycophenolate mofetil in a renal transplant recipient--a case report. 2000 Transplant. Proc. pmid:11120003
Shibata T et al. Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart? 1993 Transplant. Proc. pmid:7680147
Martínez-Castelao A et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. 2005 Transplant. Proc. pmid:16386539
Cofan F et al. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. 2005 Transplant. Proc. pmid:16386540
Spagnoletti G et al. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. 2009 Transplant. Proc. pmid:19460509
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Horimoto H et al. Hepatocyte xenotransplantation for Nagase's analbuminemic rats: the effect of FK506. 1996 Transplant. Proc. pmid:8623421
Bilodeau JF et al. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. 2009 Transplant. Proc. pmid:19917367
McAlister VC et al. Cost of liver transplantation using tacrolimus. 1998 Transplant. Proc. pmid:9636611
Tekgündüz E et al. Electrolyte free water clearance could be an early sign of renal dysfunction in renal transplant patients. 2009 Transplant. Proc. pmid:19917375
Lipson DA et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. 1998 Transplant. Proc. pmid:9636612
Zawiasa A et al. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. 2009 Jan-Feb Transplant. Proc. pmid:19249511
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Hohage H et al. Cyclosporine and tacrolimus: influence on cardiovascular risk factors. 2005 Transplant. Proc. pmid:15848615
Yasutomi M et al. Mechanism of antibody production in hamster-to-rat concordant xenotransplantation: establishment of a simple model using intravenous injection of concordant splenocytes. 1994 Transplant. Proc. pmid:7518110
Porayko MK et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533358
Mueller AR et al. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. 1995 Transplant. Proc. pmid:7533359
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Kita J et al. Effects of tacrolimus on small and large bowel anastomoses in the rat. 1999 Transplant. Proc. pmid:10578292
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
Kurnatowska I et al. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. 2011 Transplant. Proc. pmid:21996199
Iga C et al. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. 1990 Transplant. Proc. pmid:1697118
Ebbs A et al. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. 2002 Transplant. Proc. pmid:12176404
Weimer R et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. 2005 Transplant. Proc. pmid:15919463
Heilman RL et al. Steroid avoidance immunosuppression in low-risk kidney transplant recipients. 2005 Transplant. Proc. pmid:15919466
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Aktürk S et al. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection. 2017 Transplant. Proc. pmid:28340806
Bortman GV et al. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens. 2010 Jan-Feb Transplant. Proc. pmid:20172342
Escartín A et al. Analysis of pig-MAP after small bowel transplantation in pigs. 1998 Transplant. Proc. pmid:9865377
Reis A et al. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. 1998 Transplant. Proc. pmid:9865380
Zhu Y et al. Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents. 1997 Feb-Mar Transplant. Proc. pmid:9123011
Naraghi RM et al. Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123013
Meçule A et al. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen. 2011 Transplant. Proc. pmid:21620040
Platz KP et al. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. 1996 Transplant. Proc. pmid:8907933
Velio P et al. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. 1996 Transplant. Proc. pmid:8907936
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Matsuura T et al. Organ-specific tolerance induced by intrathymic injection of donor bone marrow cells and FK 506 or antilymphocyte serum in rat heart transplantation. 1994 Transplant. Proc. pmid:7520616
Boots JM et al. Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after renal transplantation? 2002 Transplant. Proc. pmid:12493409
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Peraira JR et al. High incidence of severe infections in heart transplant recipients receiving tacrolimus. 2003 Transplant. Proc. pmid:12962875
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Okamoto M et al. Tacrolimus-based immunosuppression in renal transplantation: 78 experiences in a single Japanese center. 2002 Transplant. Proc. pmid:12176527
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Lee HK et al. Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. 2016 Transplant. Proc. pmid:27320607
Walgenbach KJ et al. Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123418
Chen YB et al. Suitable calcineurin inhibitor concentrations for liver transplant recipients in the Chinese population. 2011 Transplant. Proc. pmid:21693271
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Cai X et al. Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. 1992 Transplant. Proc. pmid:1379759
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Langrehr JM et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. 2001 Transplant. Proc. pmid:11377549
Nagashima N et al. Immunocompetence assay for net effect of combined immunosuppression. 2001 Transplant. Proc. pmid:11377556
Baran DA et al. Tacrolimus and cardiac transplantation: a comparison of monotherapy and steroid-dependent patients. 2002 Transplant. Proc. pmid:12176599
Calconi G and Vianello A One-year follow-up of a large European trial comparing dual versus triple tacrolimus-based immunosuppressive regimens following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267173
Lang M et al. Combined liver-kidney transplantation: long-term follow-up in 18 patients. 1998 Transplant. Proc. pmid:9723313
Ghio L et al. Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. 2004 Transplant. Proc. pmid:15251325
Ju MK et al. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety. 2013 Transplant. Proc. pmid:23726602
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Markus BH et al. Daclizumab induction therapy in combination with tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267354
Langrehr JM et al. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267360
Ito T et al. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. Transplant. Proc. pmid:26915883
Kim YE and Eun SC Effect of FK506 ointment (Protopic) on rat skin allograft model. 2014 Transplant. Proc. pmid:24815165
González MG et al. Comparison of post-liver transplantation electrocardiographic alterations between cyclosporine- and tacrolimus-treated patients. 1999 Transplant. Proc. pmid:10500652
González-Pinto I et al. Usefulness of the switch to tacrolimus in liver transplantation. 1999 Transplant. Proc. pmid:10500653
Shingaki S et al. Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. Transplant. Proc. pmid:29407317
Manzia TM et al. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients. Transplant. Proc. pmid:29407305
Umbro I et al. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients. 2012 Transplant. Proc. pmid:22974867
Starzl TE et al. Notes on FK 506. 1991 Transplant. Proc. pmid:1714647
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Sevmis S et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. 2007 Transplant. Proc. pmid:17524935
Kolonko A et al. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. 2016 Transplant. Proc. pmid:27932154
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Pillet A et al. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia. 2006 Transplant. Proc. pmid:16980083
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947